Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-11
1999-11-30
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 93, A61K 31435, C07D22106
Patent
active
059943645
ABSTRACT:
The invention relates to compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, Y, A, B, X, a, b, c, d, v, and w are as described herein. The compounds of formula (1.0) are useful for inhibiting tumor growth.
REFERENCES:
patent: 4826853 (1989-05-01), Piwinski et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5151423 (1992-09-01), Piwinski et al.
patent: 5393890 (1995-02-01), Syoji et al.
patent: 5661152 (1997-08-01), Bishop et al.
patent: 5672611 (1997-09-01), Doll et al.
patent: 5684013 (1997-11-01), Afonso et al.
patent: 5696121 (1997-12-01), Bishop et al.
patent: 5700806 (1997-12-01), Doll et al.
patent: 5703090 (1997-12-01), Afonso et al.
patent: 5712280 (1998-01-01), Doll et al.
patent: 5714609 (1998-02-01), Bishop et al.
patent: 5719148 (1998-02-01), Bishop et al.
patent: 5721236 (1998-02-01), Bishop et al.
patent: 5728703 (1998-03-01), Bishop et al.
Bishop et al., The Journal of Biological Chemistry, vol. 270, No. 15, pp. 30611-30618 (1995).
Njoroge et al., Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 24, pp. 2977-2982 (1996).
Doll Ronald J.
Njoroge F. George
Remiszewski Stacy W.
Aulakh Charanjit S.
Jeanette Henry C.
Kight John
Schering Corporation
LandOfFree
Tricyclic antitumor farnesyl protein transferase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic antitumor farnesyl protein transferase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic antitumor farnesyl protein transferase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672981